Skip to content

Effectiviteit van de Melodic Intonation Therapy (MIT).

The efficacy of Melodic Intonation Therapy (MIT) in aphasia rehabilitation.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON28581
Enrollment
80
Registered
2009-08-19
Start date
2009-10-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

aphasia verbal apraxia afasie verbale apraxie

Interventions

Melodic Intonation Therapy (MIT): Language production therapy in which the melodic aspects of language (rythm, intonation) are used to train the production of sentences. MIT is given for 6 weeks, 5 h

Sponsors

Rijndam revalidatiecentrum Rotterdam, the Netherlands
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Aphasia after LH stroke; 2. Time post onset: 2-3 months (post-acute group) or > 1 year (chronic group); 3. Native speaker of Dutch; 4. Candidate for MIT: A. Nonfluent (5 and AAT subtest auditory comprehension > 32). 5. Age: 18-80 years; 6. Right-handed.

Exclusion criteria

Exclusion criteria: 1. Severe hearing deficit; 2. Premorbid dementia; 3. Recent psychiatric history.

Design outcomes

Primary

MeasureTime frame
CIU's/minute on the Sabadel: 1. CIU (correct information units): Words in the patients' production that are adequate, comprehensible, relevant, and informative in relation to the target story; 2. In the Sabadel task, the examiner reads a story to the patient. The story is supported by pictures. The patient's task is to retell the story, while looking at the pictures.

Secondary

MeasureTime frame
1. Repetition of trained and untrained items; 2. AAT (interview, repetition, picture description); 3. ANELT.

Contacts

Public ContactA.C. Meulen, van der

Rijndam Rehabilitation Centre Afasieteam Westersingel 300

ivandermeulen@rijndam.nl+31 (0)10-2412412, toestel 276

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)